Fig. 6From: Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trialCumulative incidence of leukemia relapse (A) and non-relapse mortality (NRM) (B). A, B Stratified according to whether patients receiving MSCs post-randomizationBack to article page